CMS Report Shows Medicare Advantage Plan Performance and Quality Continue to Improve
On Friday, the Centers for Medicare & Medicaid Services (CMS) released data on Medicare Advantage (MA) plan performance and quality.
EMA Posts Final Decision on Clinical Trial Data Transparency
After a year and a half of discussion, revisions and more than 1,000 various stakeholder comments, the European Medicines Agency (EMA) just announced its final decision on clinical trial data transparency.
Barriers to the Implementation of Patient-Reported Outcome Based Performance Measures for Assessing Quality
The pressure to constrain healthcare costs, maximize clinical quality and improve patient experience has stimulated new approaches to measuring value, and places greater focus on the use of patient-reported outcome (PRO) based performance measures.
Avalere Analysis finds In-Network Coverage of Select CSCs and Affiliated Specialty Physicians Highly Variable
A new analysis by Avalere Health, sponsored by the American Heart Association, examined the extent to which qualified health plans (QHPs) offered on the health insurance exchanges included selected comprehensive stroke centers (CSCs) and certain affiliated cardiologists, neurologists and diagnostic radiologists in their provider networks.
Avalere Issues White Paper on the Management of High-Risk Medicare Populations in Partnership with The SCAN Foundation
New Avalere research for The SCAN Foundation demonstrates the ROI potential of well-targeted care coordination programs supported by robust data.
HHS Report Finds Carrier Participation in Exchanges Will Grow 25 Percent
On September 23, HHS released a new report that finds the number of issuers participating in the 2015 exchange market will grow by 25 percent when compared to 2014.
Unique Device Identification (UDI) – 10 Things You Need to Know
Here is a list of ten things one must know about Unique Device Identification (UDI).
Avalere Analysis Finds Exchange Coverage of Drugs Used to Treat Patients with Rare Diseases Varies
A new analysis from Avalere Health, published today in the "Journal of Managed Care & Specialty Pharmacy," examined exchange coverage rates of 11 drugs used to treat rare diseases and found that plans in the exchange cover these drugs 65 percent of the time on average across plans, although coverage varies widely by product and metal level.
Avalere Analysis Reveals Significant Consolidation Among PDPs
According to a new Avalere Health analysis of the Centers for Medicare & Medicaid Services' (CMS) Landscape Files for 2015, the number of Part D standalone prescription drug plans (PDPs) will shrink by about 14 percent, from 1,169 in 2014 to 1,001 in 2015.
Exchange Enrollment Down to 7.3M
On Sept. 18, the Centers for Medicare and Medicaid Services (CMS) Administrator Marilyn Tavenner told Congress that there are currently 7.3 million people enrolled in health insurance plans on the exchanges.
ACO Performance Results Demonstrate Savings to Medicare, Minimal Savings to Individual ACOs
On Sept. 16, CMS released aggregate financial and quality results from Performance Year (PY) 2 of the Pioneer program and PY1 of the Medicare Shared Savings Program (MSSP).
CMS Medicare Landscape Files: Attention Focused on MA Plan Participation; Low-Cost PDPs Poised To Compete
The Centers for Medicare & Medicaid Services (CMS) is expected to release landscape files containing data on plan participation, premiums, and benefit designs for the 2015 Medicare Part D and Medicare Advantage (MA) markets.
Avalere Analysis: WellPoint, Blues Capture Greatest Percentage of 2014 Exchange Market Share
A new analysis from Avalere Health finds that in 12 of 15 states where complete data on market share of the health insurance exchanges are available, WellPoint or independent Blue Cross Blue Shield plans captured the greatest percentage of covered lives.
CMS Released Final Rule with Modifications to the 2014 EHR Incentive Program
On Friday, Aug. 29, CMS issued the Modifications to the Medicare and Medicaid Electronic Health Record (EHR) Program final rule, following CMS' notice of proposed rulemaking (NPRM) issued on May 20.
HHS Finalizes Re-Enrollment and Annual Eligibility Redeterminations Rule for Exchange Participation and Insurance Affordability Programs, Finalizing Most Provisions as Proposed
On Sept. 2, HHS released a final rule on re-enrollment and annual eligibility redeterminations for health insurance exchanges, simultaneously releasing guidance for issuers on discontinuation and renewal notices.
Avalere Health Expands Health Policy Expertise
New team members add depth and experience across multiple health policy issues.
Avalere Health Releases Report on Improving Access to Clinical Trial Data
A new report from Avalere Health explores the potential public health consequences of increased clinical trial data transparency.
Avalere Analysis: ‘Copper Plan’ Alternative Would Lower Premiums 18%
In an analysis funded by the Council for Affordable Health Coverage, Avalere Health estimated the cost savings resulting from a new, less-expensive tier of insurance coverage, if legislation were to permit it.
FDA Receives First Biosimilar Application for a Monoclonal Antibody
On August 11, Celltrion announced the completion of their 351(k) filing procedure to FDA on Aug. 8, for its Remicade (infliximab) biosimilar product, Remsima (infliximab).
Notable Success for Parallel Review Program, but Uncertainty about Program’s Future
On Aug. 11, Cologuard became the first technology to receive a simultaneous FDA approval and proposed Medicare national coverage determination (NCD) through the FDA-CMS Parallel Review program.